title: Targeting metastatic prostate cancer: the search for innovative systemic therapies.
abstract: Metastatic hormone-resistant prostate cancer has proven largely resistant to cytotoxic therapy. Since 2004, docetaxel (Taxotere)/prednisone has become the standard chemotherapy used to treat advanced hormone-resistant prostate cancer. However, the survival advantage is modest and a significant number of patients do not respond to chemotherapy. It is hoped that an increased understanding of the mechanisms underlying the progression of prostate cancer will lead to new treatment modalities. With the growing number of biologic and targeted agents under development, the potential armamentarium of prostate cancer treatments is steadily growing. However, none of the new treatment modalities has yet been shown to be more effective than standard treatments. This article will provide an overview of targeted or innovative therapies in the treatment of prostate cancer.
authors.affiliation: Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto Toronto, Ontario, Canada. dominik.berthold@uhn.on.ca
authors.forename: Dominik R
authors.initials: DR
authors.lastname: Berthold
authors.forename: Malcolm J
authors.initials: MJ
authors.lastname: Moore
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery
chemical_list: D000726:Androgen Antagonists